Protocol for the Nutrition OUtReach
Top Things to Know
The central hypothesis is that medically tailored food provision can function as part of supportive clinical care, reducing malnutrition during an intensive treatment period and potentially affecting downstream complications and healthcare use.
The study's combination of standardized nutrition targets with flexibility for regional foods and individual preferences could inform FIM implementation in other specialty-care settings.
The potential evidence that MTGs reduce malnutrition or complications and offer favorable value could strengthen the case for integrating FIM into specialty-care payment models.
Summary of Conclusion/Findings
The NOURISH trial is a phase II, multicenter randomized controlled trial testing medically tailored groceries (MTGs) among 210 food-insecure patients ages 8–80 undergoing hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy at four U.S. cancer centers. Participants will be randomized 1:1 to receive either MTGs plus food-bank information or food-bank information alone; the intervention provides MTGs twice weekly during the intensive peri-treatment period, with less frequent provision afterward, and tailors foods for medical restrictions, allergies, and cultural or religious preferences while standardizing nutrient composition. The primary endpoint is malnutrition through day 100, and investigators have powered the trial to detect a 20-percentage-point difference, hypothesizing rates of 70% in the control group versus 50% with MTGs. The study will also assess diet quality, food insecurity, infections, graft-versus-host disease, survival, quality of life, financial toxicity, functional outcomes, health care use and costs through 1 year, with exploratory analyses of muscle health and the gut microbiome. Importantly for implementation, NOURISH pairs each cancer center with a local food bank and incorporates input from registered dietitian nutritionists, patients and community partners to adapt the groceries to regional preferences while maintaining common nutrition standards. Enrollment began in May 2025 and is planned through May 2029, so the protocol reports no trial outcomes yet and its proposed clinical and economic benefits remain hypotheses to be tested.